|
|
|
|
|
||
|
A good drug development candidate is worth tens or even hundreds of millions of dollars. Given the highly competitive nature of pharma research, it is critical that researchers fully exploit all available sources of information. However, as the human genome project approaches completion, pharmaceutical researchers are being swamped by data from both the public and private domain. The multi-billion dollar worldwide investment in the human genome has generated tens of thousands of sequences. Aggravating this situation, the biomedical literature consists of nearly 10 million records which represents a huge resource that is not being effectively used. InPharmix Incorporated is creating the tools required to exploit this wealth of data. |
What's New!
|
InPharmix Incorporated provides pharmaceutical and biotechnology researchers the tools necessary to maximize the value of public and proprietary genomic and scientific literature databases. InPharmix accomplishes this by offering clients the pharma focused bioinformatics and literature mining capabilities necessary for the genomic era. Products offered by InPharmix include proprietary bioinformatics and text mining software, custom application development, and bioinformatics consulting services, all of which are specifically focused on the needs of the pharma researcher.